Evidence map›Paper›PMID 42185298›Full record

ArticleNature communications2026

Long-read deep sequencing reveals high rates of multilineage transmission and rapid viral population changes in acute HIV infection.

James I Mullins, Wenjie Deng, Elena E Giorgi, Craig A Magaret, Morgane Rolland, Tanmoy Bhattacharya, Dylan H Westfall, Anna E J Yssel, Roger E Bumgarner, Ben Murrell and 25 more

2 registry-linked trialsAbstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02568215 phase2completednot on this map

A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2016 to 2021Enrolled1,924ConditionsHIV InfectionsArmsVRC01, Placebo for VRC01
NCT02716675 phase2completednot on this map

A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2016 to 2020Enrolled2,699ConditionsHIV InfectionsArmsVRC01, Placebo for VRC01
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

35 authors.

James I MullinsDepartment of Microbiology, University of Washington, Seattle, WA, USA. jmullins@uw.edu.ORCID http://orcid.org/0000-0002-4461-8158
Wenjie DengDepartment of Microbiology, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-7567-4489
Elena E GiorgiVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Craig A MagaretVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-5056-2664
Morgane RollandHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-3650-8490
Tanmoy BhattacharyaTheoretical Division, Los Alamos National Laboratory, Los Alamos, NM, USA.ORCID http://orcid.org/0000-0002-1060-652X
Dylan H WestfallDepartment of Microbiology, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-2434-8525
Anna E J YsselInstitute of Infectious Diseases and Molecular Medicine, Division of Medical Virology, University of Cape Town, Cape Town, South Africa.ORCID http://orcid.org/0000-0003-1165-3237
Roger E BumgarnerDepartment of Microbiology, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-8168-6985
Ben MurrellDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Thumbi Ndung'uAfrican Health Research Institute, University of KwaZulu Natal, Durban, South Africa.ORCID http://orcid.org/0000-0003-2962-3992
Merlin L RobbHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-3949-9649
Raabya RossenkhanVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Paul T EdlefsenVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-8393-8103
Krista L DongRagon Institute of Mass General Brigham, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.
Lennie ChenDepartment of Microbiology, University of Washington, Seattle, WA, USA.
Asanda Gwashu-NyangiweInstitute of Infectious Diseases and Molecular Medicine, Division of Medical Virology, University of Cape Town, Cape Town, South Africa.
Hong ZhaoDepartment of Microbiology, University of Washington, Seattle, WA, USA.
Ruwayhida ThebusInstitute of Infectious Diseases and Molecular Medicine, Division of Medical Virology, University of Cape Town, Cape Town, South Africa.
Nonkululeko NdabambiInstitute of Infectious Diseases and Molecular Medicine, Division of Medical Virology, University of Cape Town, Cape Town, South Africa.
Bruna GalvaoInstitute of Infectious Diseases and Molecular Medicine, Division of Medical Virology, University of Cape Town, Cape Town, South Africa.ORCID http://orcid.org/0009-0007-9189-1521
Fredrick SaweKenya Medical Research Institute, Walter Reed Army Institute of Research-Africa, Nairobi, Kenya.
Sorachai NitayaphanArmed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
Talita YorkInstitute of Infectious Diseases and Molecular Medicine, Division of Medical Virology, University of Cape Town, Cape Town, South Africa.ORCID http://orcid.org/0000-0003-2884-3010
David MattenInstitute of Infectious Diseases and Molecular Medicine, Division of Medical Virology, University of Cape Town, Cape Town, South Africa.
Hugh MurrellInstitute of Infectious Diseases and Molecular Medicine, Division of Medical Virology, University of Cape Town, Cape Town, South Africa.ORCID http://orcid.org/0000-0002-6185-9885
Alec P PankowDepartment of Microbiology, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-9108-1683
Michal JuraskaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-0920-2915
James LudwigVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-3500-3490
John HuralVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Myron S CohenUniversity of North Carolina, Chapel Hill, NC, USA.
Lawrence CoreyVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-2179-2436
M Juliana McElrathVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-2276-7117
Peter B GilbertVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Carolyn WilliamsonInstitute of Infectious Diseases and Molecular Medicine, Division of Medical Virology, University of Cape Town, Cape Town, South Africa.ORCID http://orcid.org/0000-0003-0125-1226

Funding

LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6M
LC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6M
SDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9M
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ARTHUR Y KIM · 2004 to 2026
$94.4M
Bill & Melinda Gates Foundation INV-016189Bill & Melinda Gates Foundation INV-033558Gates Foundation INV-016189Gates Foundation INV-033558Gilead Sciences (Gilead) 19275Henry M. Jackson Foundation (Henry M. Jackson Foundation for the Advancement of Military Medicine) W81XWH-11-2-0174International AIDS Vaccine Initiative (International AIDS Vaccine Initiative, Inc.) UKZNRSA1001NIAID NIH HHS P30 AI060354NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI068618NIAID NIH HHS UM1 AI068635
6 · The paper itself

Abstract

Understanding the selective forces acting upon HIV early in infection is crucial to design prevention strategies. By leveraging deep sequencing and the short diagnostic intervals of the FRESH and RV217 cohorts between the last-negative and first-positive RNA tests (median 4 days), we captured a precise and early snapshot of acute HIV infection. The frequency of multiple transmitted viruses of 37% in these as well as placebo recipients from the AMP trials (NCT02716675 and NCT02568215) was higher than previously published, with the true frequency likely to be higher. The relative abundance of lineages fluctuated substantially over time in two-thirds of the multilineage infections, generating uncertainty in identifying the specific viruses that were transmitted and founding the infection. At the population level, viral populations exhibited limited diversity and selection on the Gag and Env proteins at the earliest times examined, with sites inferred to be undergoing negative selection most evident. These data may help explain vaccination failures and provide new targets for prevention.

Indexed as

HIV-1HIV Infectionsenv Gene Products, Human Immunodeficiency VirusHigh-Throughput Nucleotide SequencingHumansPhylogenyRNA, Viralenv Gene Products, Human Immunodeficiency VirusRNA, Viral

Identifiers

PMID42185298
PMCPMC13385744

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.